Abstract
Stevia rebaudiana Bertoni is a sweet and nutrient-rich plant belonging to the Asteraceae family. Stevia leaves contain steviol glycosides including stevioside, rebaudioside (A to F), steviolbioside, and isosteviol, which are responsible for the plant’s sweet taste, and have commercial value all over the world as a sugar substitute in foods, beverages and medicines. Among the various steviol glycosides, stevioside, rebaudioside A and rebaudioside C are the major metabolites and these compounds are on average 250-300 times sweeter than sucrose. Steviol is the final product of Stevia metabolism. The metabolized components essentially leave the body and there is no accumulation. Beyond their value as sweeteners, Stevia and its glycosdies possess therapeutic effects against several diseases such as cancer, diabetes mellitus, hypertension, inflammation, cystic fibrosis, obesity and tooth decay. Studies have shown that steviol glycosides found in Stevia are not teratogenic, mutagenic or carcinogenic and cause no acute and subacute toxicity. The present review provides a summary on the biological and pharmacological properties of steviol glycosides that might be relevant for the treatment of human diseases.
Keywords: Stevia, steviol glycosides, stevioside, rebaudiosides A, cancer, diabetes, toxicity.
Current Pharmaceutical Design
Title:A Review on the Pharmacology and Toxicology of Steviol Glycosides Extracted from Stevia rebaudiana
Volume: 23 Issue: 11
Author(s): Amir Abbas Momtazi-Borojeni, Seyed-Alireza Esmaeili, Elham Abdollahi and Amirhossein Sahebkar*
Affiliation:
- Department of Medical Biotechnology, Mashhad University of Medical Sciences, Mashhad 9177948564,Iran
Keywords: Stevia, steviol glycosides, stevioside, rebaudiosides A, cancer, diabetes, toxicity.
Abstract: Stevia rebaudiana Bertoni is a sweet and nutrient-rich plant belonging to the Asteraceae family. Stevia leaves contain steviol glycosides including stevioside, rebaudioside (A to F), steviolbioside, and isosteviol, which are responsible for the plant’s sweet taste, and have commercial value all over the world as a sugar substitute in foods, beverages and medicines. Among the various steviol glycosides, stevioside, rebaudioside A and rebaudioside C are the major metabolites and these compounds are on average 250-300 times sweeter than sucrose. Steviol is the final product of Stevia metabolism. The metabolized components essentially leave the body and there is no accumulation. Beyond their value as sweeteners, Stevia and its glycosdies possess therapeutic effects against several diseases such as cancer, diabetes mellitus, hypertension, inflammation, cystic fibrosis, obesity and tooth decay. Studies have shown that steviol glycosides found in Stevia are not teratogenic, mutagenic or carcinogenic and cause no acute and subacute toxicity. The present review provides a summary on the biological and pharmacological properties of steviol glycosides that might be relevant for the treatment of human diseases.
Export Options
About this article
Cite this article as:
Momtazi-Borojeni Abbas Amir, Esmaeili Seyed-Alireza, Abdollahi Elham and Sahebkar Amirhossein*, A Review on the Pharmacology and Toxicology of Steviol Glycosides Extracted from Stevia rebaudiana, Current Pharmaceutical Design 2017; 23 (11) . https://dx.doi.org/10.2174/1381612822666161021142835
DOI https://dx.doi.org/10.2174/1381612822666161021142835 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural Insight into PPARγ Ligands Binding
Current Medicinal Chemistry State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research
Current Diabetes Reviews Computer-Based Comparison of Structural Features of Envelope Protein of Alkhurma Hemorrhagic Fever Virus with the Homologous Proteins of Two Closest Viruses
Protein & Peptide Letters Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders
Current Neurovascular Research Peptides As Therapeutics with Enhanced Bioactivity
Current Medicinal Chemistry Angiotensin-Receptor Blockers and the Risk of Alzheimer´s Disease: A Meta-analysis
Current Reviews in Clinical and Experimental Pharmacology Association Between C1236T (rs1128503) Variant in ABCB1 Gene and Breast Cancer Recurrence
Clinical Cancer Drugs Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews The Nitric Oxide Signaling Pathway in the Penis
Current Pharmaceutical Design Prevalence and Associates of Foot Deformities among Patients with Diabetes in Jordan
Current Diabetes Reviews Innovative Models for the Empowerment of Patients with Type 2 Diabetes: The CAIPaDi Program
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Development, Optimization & Evaluation of Porous Chitosan Scaffold Formulation of Gliclazide for the Treatment of Type-2 Diabetes Mellitus
Drug Delivery Letters FOXO1: A Potential Target for Human Diseases
Current Drug Targets Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
Current Pharmaceutical Design Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets